O ROURKE & COMPANY Inc Sells 183 Shares of Merck & Co., Inc. $MRK

O ROURKE & COMPANY Inc lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 3.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,692 shares of the company’s stock after selling 183 shares during the period. O ROURKE & COMPANY Inc’s holdings in Merck & Co., Inc. were worth $451,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Broadway Wealth Solutions Inc. grew its position in Merck & Co., Inc. by 16.0% in the 2nd quarter. Broadway Wealth Solutions Inc. now owns 6,339 shares of the company’s stock worth $502,000 after purchasing an additional 876 shares during the period. Powers Advisory Group LLC grew its position in Merck & Co., Inc. by 4.6% in the 2nd quarter. Powers Advisory Group LLC now owns 3,042 shares of the company’s stock worth $241,000 after purchasing an additional 135 shares during the period. Bourgeon Capital Management LLC grew its position in Merck & Co., Inc. by 7.2% in the 2nd quarter. Bourgeon Capital Management LLC now owns 160,906 shares of the company’s stock worth $12,737,000 after purchasing an additional 10,748 shares during the period. Union Bancaire Privee UBP SA increased its holdings in Merck & Co., Inc. by 322.8% during the second quarter. Union Bancaire Privee UBP SA now owns 367,101 shares of the company’s stock valued at $30,456,000 after buying an additional 280,275 shares during the last quarter. Finally, MBA Advisors LLC increased its holdings in Merck & Co., Inc. by 67.1% during the second quarter. MBA Advisors LLC now owns 7,590 shares of the company’s stock valued at $601,000 after buying an additional 3,047 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $83.96 on Wednesday. The firm has a fifty day moving average price of $82.55 and a 200-day moving average price of $81.71. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The stock has a market cap of $209.71 billion, a PE ratio of 12.94, a price-to-earnings-growth ratio of 0.81 and a beta of 0.37. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $114.79.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th will be issued a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date is Monday, September 15th. Merck & Co., Inc.’s payout ratio is currently 49.92%.

Wall Street Analyst Weigh In

MRK has been the topic of several recent research reports. Morgan Stanley decreased their price target on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Wells Fargo & Company decreased their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Finally, Berenberg Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price target for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Hold” and a consensus price target of $106.41.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.